Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR-T for Relapsed/Refractory B-cell ALL
NCT03263208Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Aug 2017
- Primary completion
- Jan 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Autologous CD19 CAR-T (Institute of Hematology & Blood Diseases Hospital) in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Henan Cancer Hospital. Status: unknown.
02
Drugs
Autologous CD19 CAR-T (Institute of Hematology & Blood Diseases Hospital)
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT03263208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03263208.